ID   NUDT5_HUMAN             Reviewed;         219 AA.
AC   Q9UKK9; A8K516; Q6IAG0; Q9UH49;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   10-MAY-2017, entry version 155.
DE   RecName: Full=ADP-sugar pyrophosphatase;
DE            EC=3.6.1.13 {ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:21389046};
DE   AltName: Full=8-oxo-dGDP phosphatase;
DE            EC=3.6.1.58 {ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:19699693, ECO:0000269|PubMed:21389046};
DE   AltName: Full=Nuclear ATP-synthesis protein NUDIX5 {ECO:0000305|PubMed:27257257};
DE            EC=2.7.7.96 {ECO:0000269|PubMed:27257257};
DE   AltName: Full=Nucleoside diphosphate-linked moiety X motif 5 {ECO:0000305};
DE            Short=Nudix motif 5 {ECO:0000305};
DE            Short=hNUDT5 {ECO:0000303|PubMed:21768126};
DE   AltName: Full=YSA1H {ECO:0000303|PubMed:10567213};
GN   Name=NUDT5; Synonyms=NUDIX5 {ECO:0000303|PubMed:27257257};
GN   ORFNames=HSPC115 {ECO:0000303|PubMed:11042152};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=10567213; DOI=10.1042/bj3440331;
RA   Gasmi L., Cartwright J.L., McLennan A.G.;
RT   "Cloning, expression and characterization of YSA1H, a human adenosine
RT   5'-diphosphosugar pyrophosphatase possessing a MutT motif.";
RL   Biochem. J. 344:331-337(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10722730; DOI=10.1074/jbc.275.12.8844;
RA   Yang H., Slupska M.M., Wei Y.-F., Tai J.H., Luther W.M., Xia Y.-R.,
RA   Shih D.M., Chiang J.-H., Baikalov C., Fitz-Gibbon S., Phan I.T.,
RA   Conrad A., Miller J.H.;
RT   "Cloning and characterization of a new member of the Nudix hydrolases
RT   from human and mouse.";
RL   J. Biol. Chem. 275:8844-8853(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-74, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19699693; DOI=10.1016/j.dnarep.2009.07.011;
RA   Kamiya H., Hori M., Arimori T., Sekiguchi M., Yamagata Y.,
RA   Harashima H.;
RT   "NUDT5 hydrolyzes oxidized deoxyribonucleoside diphosphates with broad
RT   substrate specificity.";
RL   DNA Repair 8:1250-1254(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-210 AND LYS-218, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-10, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=21389046; DOI=10.1093/jb/mvr028;
RA   Ito R., Sekiguchi M., Setoyama D., Nakatsu Y., Yamagata Y.,
RA   Hayakawa H.;
RT   "Cleavage of oxidized guanine nucleotide and ADP sugar by human NUDT5
RT   protein.";
RL   J. Biochem. 149:731-738(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-3, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBUNIT, INDUCTION, INTERACTION WITH PARG, PHOSPHORYLATION
RP   AT THR-45, AND MUTAGENESIS OF THR-45 AND GLU-112.
RX   PubMed=27257257; DOI=10.1126/science.aad9335;
RA   Wright R.H., Lioutas A., Le Dily F., Soronellas D., Pohl A., Bonet J.,
RA   Nacht A.S., Samino S., Font-Mateu J., Vicent G.P., Wierer M.,
RA   Trabado M.A., Schelhorn C., Carolis C., Macias M.J., Yanes O.,
RA   Oliva B., Beato M.;
RT   "ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for
RT   chromatin remodeling.";
RL   Science 352:1221-1225(2016).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-210 IN COMPLEX WITH AMP;
RP   MAGNESIUM IONS AND ADP-RIBOSE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT,
RP   AND COFACTOR.
RX   PubMed=17052728; DOI=10.1016/j.jmb.2006.09.078;
RA   Zha M., Zhong C., Peng Y., Hu H., Ding J.;
RT   "Crystal structures of human NUDT5 reveal insights into the structural
RT   basis of the substrate specificity.";
RL   J. Mol. Biol. 364:1021-1033(2006).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-210 IN COMPLEX WITH AMPCPR
RP   AND MAGNESIUM IONS, COFACTOR, MUTAGENESIS OF TRP-28; TRP-46; ARG-51;
RP   ARG-84; LEU-98; GLU-112; GLU-116 AND GLU-166, AND SUBUNIT.
RX   PubMed=18462755; DOI=10.1016/j.jmb.2008.04.006;
RA   Zha M., Guo Q., Zhang Y., Yu B., Ou Y., Zhong C., Ding J.;
RT   "Molecular mechanism of ADP-ribose hydrolysis by human NUDT5 from
RT   structural and kinetic studies.";
RL   J. Mol. Biol. 379:568-578(2008).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 13-208 IN COMPLEX WITH
RP   8-OXO-DGDP; 8-OXO-DGMP; 8-OXO-DADP AND MANGANESE IONS, COFACTOR, AND
RP   SUBUNIT.
RX   PubMed=21768126; DOI=10.1093/nar/gkr575;
RA   Arimori T., Tamaoki H., Nakamura T., Kamiya H., Ikemizu S., Takagi Y.,
RA   Ishibashi T., Harashima H., Sekiguchi M., Yamagata Y.;
RT   "Diverse substrate recognition and hydrolysis mechanisms of human
RT   NUDT5.";
RL   Nucleic Acids Res. 39:8972-8983(2011).
CC   -!- FUNCTION: Enzyme that can either act as an ADP-sugar
CC       pyrophosphatase in absence of diphosphate or catalyze the
CC       synthesis of ATP in presence of diphosphate (PubMed:27257257). In
CC       absence of diphosphate, hydrolyzes with similar activities various
CC       modified nucleoside diphosphates such as ADP-ribose, ADP-mannose,
CC       ADP-glucose, 8-oxo-GDP and 8-oxo-dGDP (PubMed:10567213,
CC       PubMed:10722730, PubMed:19699693, PubMed:21389046,
CC       PubMed:17052728). Can also hydrolyze other nucleotide sugars with
CC       low activity (PubMed:19699693, PubMed:21389046). In presence of
CC       diphosphate, mediates the synthesis of ATP in the nucleus by
CC       catalyzing the conversion of ADP-ribose to ATP and ribose 5-
CC       phosphate. Nuclear ATP synthesis takes place when dephosphorylated
CC       at Thr-45 (PubMed:27257257). Nuclear ATP generation is required
CC       for extensive chromatin remodeling events that are energy-
CC       consuming (PubMed:27257257). Does not play a role in U8 snoRNA
CC       decapping activity (By similarity). Binds U8 snoRNA (By
CC       similarity). {ECO:0000250|UniProtKB:Q9JKX6,
CC       ECO:0000269|PubMed:10567213, ECO:0000269|PubMed:10722730,
CC       ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:19699693,
CC       ECO:0000269|PubMed:21389046, ECO:0000269|PubMed:27257257}.
CC   -!- CATALYTIC ACTIVITY: ATP + D-ribose 5-phosphate = diphosphate +
CC       ADP-D-ribose. {ECO:0000269|PubMed:27257257}.
CC   -!- CATALYTIC ACTIVITY: ADP-D-ribose + H(2)O = AMP + D-ribose 5-
CC       phosphate. {ECO:0000269|PubMed:17052728,
CC       ECO:0000269|PubMed:21389046}.
CC   -!- CATALYTIC ACTIVITY: 8-oxo-dGDP + H(2)O = 8-oxo-dGMP + phosphate.
CC       {ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:19699693,
CC       ECO:0000269|PubMed:21389046}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17052728,
CC         ECO:0000269|PubMed:18462755, ECO:0000269|PubMed:21768126};
CC       Note=Binds 3 Mg(2+) ions per subunit.
CC       {ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:18462755,
CC       ECO:0000269|PubMed:21768126};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.1 uM for 8-oxo-dGDP {ECO:0000269|PubMed:19699693};
CC         KM=2.9 uM for 8-oxo-dADP {ECO:0000269|PubMed:19699693};
CC         KM=8.8 uM for 2-oxo-dADP {ECO:0000269|PubMed:19699693};
CC         KM=4.0 uM for 5-CHO-dUDP {ECO:0000269|PubMed:19699693};
CC         KM=7.6 uM for dGDP {ECO:0000269|PubMed:19699693};
CC         KM=12.6 uM for dADP {ECO:0000269|PubMed:19699693};
CC         KM=3.8 uM for 8-oxo-dGDP (at pH 8.0)
CC         {ECO:0000269|PubMed:21389046};
CC         KM=3.5 uM for 8-oxo-dGDP (at pH 10.0)
CC         {ECO:0000269|PubMed:21389046};
CC         KM=1.9 uM for ADP-D-ribose (at pH 8.0)
CC         {ECO:0000269|PubMed:21389046};
CC         KM=36 uM for 8-oxo-dGTP (at pH 10.0)
CC         {ECO:0000269|PubMed:21389046};
CC         KM=42.6 uM for ADP-D-ribose (in the presence of diphosphate)
CC         {ECO:0000269|PubMed:27257257};
CC         Vmax=11 pmol/min/ug enzyme with 8-oxo-dGDP as substrate (at pH
CC         8.0) {ECO:0000269|PubMed:21389046};
CC         Vmax=2400 pmol/min/ug enzyme with ADP-D-ribose as substrate (at
CC         pH 8.0) {ECO:0000269|PubMed:21389046};
CC         Vmax=46 pmol/min/ug enzyme with 8-oxo-dGDP as substrate (at pH
CC         10.0) {ECO:0000269|PubMed:21389046};
CC         Vmax=1.7 pmol/min/ug enzyme with 8-oxo-dGTP as substrate (at pH
CC         10.0) {ECO:0000269|PubMed:21389046};
CC         Note=kcat is 0.369 min(-1) for 8-OH-dGDP. kcat is 0.538 min(-1)
CC         for 8-OH-dADP. kcat is 0.226 min(-1) for 2-OH-dADP. kcat is
CC         0.209 min(-1) for 5-CHO-dUDP. kcat is 0.929 min(-1) for dGDP.
CC         kcat is 0.365 min(-1) for dADP. {ECO:0000269|PubMed:19699693};
CC   -!- SUBUNIT: Homodimer (PubMed:27257257, PubMed:17052728,
CC       PubMed:18462755, PubMed:21768126). Interacts with PARG
CC       (PubMed:27257257). {ECO:0000269|PubMed:17052728,
CC       ECO:0000269|PubMed:18462755, ECO:0000269|PubMed:21768126,
CC       ECO:0000269|PubMed:27257257}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305|PubMed:27257257}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Most abundant in liver.
CC       {ECO:0000269|PubMed:10722730}.
CC   -!- INDUCTION: Overexpressed in cancer patients with a poor outcome.
CC       {ECO:0000269|PubMed:27257257}.
CC   -!- PTM: Phosphorylation at Thr-45 is required for homodimer
CC       stability; dephosphorylation results in destabilization of the
CC       homodimer. Dephosphorylation at Thr-45 promotes the ATP-synthesis
CC       activity. {ECO:0000269|PubMed:27257257}.
CC   -!- SIMILARITY: Belongs to the Nudix hydrolase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF155832; AAF06734.1; -; mRNA.
DR   EMBL; AF218818; AAF25479.1; -; mRNA.
DR   EMBL; AF161464; AAF29079.1; -; mRNA.
DR   EMBL; CR457195; CAG33476.1; -; mRNA.
DR   EMBL; AK291131; BAF83820.1; -; mRNA.
DR   EMBL; CH471072; EAW86322.1; -; Genomic_DNA.
DR   EMBL; BC000025; AAH00025.1; -; mRNA.
DR   CCDS; CCDS7089.1; -.
DR   RefSeq; NP_054861.2; NM_014142.3.
DR   UniGene; Hs.555956; -.
DR   UniGene; Hs.656304; -.
DR   PDB; 2DSB; X-ray; 2.50 A; A/B/C/D=1-219.
DR   PDB; 2DSC; X-ray; 2.00 A; A/B=1-210.
DR   PDB; 2DSD; X-ray; 2.60 A; A/B=1-210.
DR   PDB; 3AC9; X-ray; 2.10 A; A/B=14-208.
DR   PDB; 3ACA; X-ray; 2.05 A; A/B=13-208.
DR   PDB; 3BM4; X-ray; 2.00 A; A/B=1-210.
DR   PDB; 3L85; X-ray; 2.30 A; A/B=14-208.
DR   PDBsum; 2DSB; -.
DR   PDBsum; 2DSC; -.
DR   PDBsum; 2DSD; -.
DR   PDBsum; 3AC9; -.
DR   PDBsum; 3ACA; -.
DR   PDBsum; 3BM4; -.
DR   PDBsum; 3L85; -.
DR   ProteinModelPortal; Q9UKK9; -.
DR   SMR; Q9UKK9; -.
DR   BioGrid; 116335; 18.
DR   IntAct; Q9UKK9; 11.
DR   MINT; MINT-1370495; -.
DR   STRING; 9606.ENSP00000419628; -.
DR   iPTMnet; Q9UKK9; -.
DR   PhosphoSitePlus; Q9UKK9; -.
DR   BioMuta; NUDT5; -.
DR   EPD; Q9UKK9; -.
DR   MaxQB; Q9UKK9; -.
DR   PaxDb; Q9UKK9; -.
DR   PeptideAtlas; Q9UKK9; -.
DR   PRIDE; Q9UKK9; -.
DR   DNASU; 11164; -.
DR   Ensembl; ENST00000491614; ENSP00000419628; ENSG00000165609.
DR   Ensembl; ENST00000537776; ENSP00000445116; ENSG00000165609.
DR   GeneID; 11164; -.
DR   KEGG; hsa:11164; -.
DR   UCSC; uc001ilj.4; human.
DR   CTD; 11164; -.
DR   GeneCards; NUDT5; -.
DR   HGNC; HGNC:8052; NUDT5.
DR   HPA; HPA019827; -.
DR   MIM; 609230; gene.
DR   neXtProt; NX_Q9UKK9; -.
DR   OpenTargets; ENSG00000165609; -.
DR   PharmGKB; PA31838; -.
DR   eggNOG; KOG3041; Eukaryota.
DR   eggNOG; COG0494; LUCA.
DR   GeneTree; ENSGT00390000006280; -.
DR   HOGENOM; HOG000174302; -.
DR   HOVERGEN; HBG052691; -.
DR   InParanoid; Q9UKK9; -.
DR   KO; K13987; -.
DR   PhylomeDB; Q9UKK9; -.
DR   TreeFam; TF106347; -.
DR   BRENDA; 3.6.1.13; 2681.
DR   BRENDA; 3.6.1.58; 2681.
DR   Reactome; R-HSA-2393930; Phosphate bond hydrolysis by NUDT proteins.
DR   SABIO-RK; Q9UKK9; -.
DR   ChiTaRS; NUDT5; human.
DR   EvolutionaryTrace; Q9UKK9; -.
DR   GeneWiki; NUDT5; -.
DR   GenomeRNAi; 11164; -.
DR   PRO; PR:Q9UKK9; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000165609; -.
DR   CleanEx; HS_NUDT5; -.
DR   ExpressionAtlas; Q9UKK9; baseline and differential.
DR   Genevisible; Q9UKK9; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0044715; F:8-oxo-dGDP phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0047631; F:ADP-ribose diphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0019144; F:ADP-sugar diphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0016779; F:nucleotidyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030515; F:snoRNA binding; ISS:UniProtKB.
DR   GO; GO:1990966; P:ATP generation from poly-ADP-D-ribose; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0019303; P:D-ribose catabolic process; IDA:UniProtKB.
DR   GO; GO:0034656; P:nucleobase-containing small molecule catabolic process; TAS:Reactome.
DR   GO; GO:0009117; P:nucleotide metabolic process; NAS:ProtInc.
DR   GO; GO:0009191; P:ribonucleoside diphosphate catabolic process; IDA:UniProtKB.
DR   InterPro; IPR020476; Nudix_hydrolase.
DR   InterPro; IPR020084; NUDIX_hydrolase_CS.
DR   InterPro; IPR000086; NUDIX_hydrolase_dom.
DR   InterPro; IPR015797; NUDIX_hydrolase_dom-like.
DR   Pfam; PF00293; NUDIX; 1.
DR   PRINTS; PR00502; NUDIXFAMILY.
DR   SUPFAM; SSF55811; SSF55811; 1.
DR   PROSITE; PS51462; NUDIX; 1.
DR   PROSITE; PS00893; NUDIX_BOX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Hydrolase; Magnesium;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; RNA-binding; Transferase.
FT   CHAIN         1    219       ADP-sugar pyrophosphatase.
FT                                /FTId=PRO_0000057048.
FT   DOMAIN       57    197       Nudix hydrolase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00794}.
FT   REGION       46     47       Substrate binding; shared with dimeric
FT                                partner. {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   MOTIF        97    118       Nudix box.
FT   METAL        96     96       Magnesium 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   METAL       112    112       Magnesium 2.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   METAL       112    112       Magnesium 3.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   METAL       116    116       Magnesium 1.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   METAL       116    116       Magnesium 3.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   METAL       166    166       Magnesium 3.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   BINDING      28     28       Substrate. {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   BINDING      51     51       Substrate; shared with dimeric partner.
FT                                {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   BINDING      84     84       Substrate. {ECO:0000269|PubMed:17052728,
FT                                ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:21768126}.
FT   BINDING      98     98       Substrate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:17052728}.
FT   BINDING     133    133       Substrate. {ECO:0000269|PubMed:17052728}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      10     10       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      45     45       Phosphothreonine.
FT                                {ECO:0000269|PubMed:27257257}.
FT   MOD_RES      74     74       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     210    210       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     218    218       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT     123    123       I -> T (in dbSNP:rs34863826).
FT                                /FTId=VAR_034159.
FT   MUTAGEN      28     28       W->A: Reduces affinity for substrate
FT                                about 8-fold. Strongly reduced catalytic
FT                                activity and strongly reduced affinity
FT                                for substrate; when associated with A-46.
FT                                {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN      45     45       T->A: Impaired phosphorylation; generates
FT                                ATP in the presence of diphosphate.
FT                                {ECO:0000269|PubMed:27257257}.
FT   MUTAGEN      45     45       T->D: Phosphomimetic mutant; unable to
FT                                generate ATP in the presence of
FT                                diphosphate.
FT                                {ECO:0000269|PubMed:27257257}.
FT   MUTAGEN      46     46       W->A: Reduces affinity for substrate
FT                                about 6-fold. Strongly reduced catalytic
FT                                activity and strongly reduced affinity
FT                                for substrate; when associated with A-28.
FT                                {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN      51     51       R->Q: Reduces affinity for substrate
FT                                about 15-fold and reduces catalytic rate
FT                                about 17-fold.
FT                                {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN      84     84       R->Q: Reduces affinity for substrate
FT                                about 5-fold and reduces catalytic rate
FT                                67-fold. {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN      98     98       L->A: Reduces affinity for substrate
FT                                about 6-fold.
FT                                {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN     112    112       E->Q: Catalytic inactive mutant for both
FT                                ADP-sugar pyrophosphatase and nuclear
FT                                ATP-synthesis activities. Reduces
FT                                catalytic rate 6300-fold.
FT                                {ECO:0000269|PubMed:18462755,
FT                                ECO:0000269|PubMed:27257257}.
FT   MUTAGEN     116    116       E->Q: Reduces catalytic rate 2000-fold.
FT                                {ECO:0000269|PubMed:18462755}.
FT   MUTAGEN     166    166       E->Q: Reduces catalytic rate 120-fold.
FT                                {ECO:0000269|PubMed:18462755}.
FT   CONFLICT     50     52       KRT -> NVP (in Ref. 2; AAF25479).
FT                                {ECO:0000305}.
FT   STRAND       16     25       {ECO:0000244|PDB:2DSC}.
FT   STRAND       27     37       {ECO:0000244|PDB:2DSC}.
FT   STRAND       43     51       {ECO:0000244|PDB:2DSC}.
FT   STRAND       60     69       {ECO:0000244|PDB:2DSC}.
FT   STRAND       76     84       {ECO:0000244|PDB:2DSC}.
FT   HELIX        85     87       {ECO:0000244|PDB:2DSC}.
FT   STRAND       89     93       {ECO:0000244|PDB:2DSC}.
FT   STRAND       96     98       {ECO:0000244|PDB:2DSC}.
FT   HELIX       105    117       {ECO:0000244|PDB:2DSC}.
FT   STRAND      122    126       {ECO:0000244|PDB:2DSC}.
FT   STRAND      130    132       {ECO:0000244|PDB:2DSC}.
FT   TURN        134    136       {ECO:0000244|PDB:2DSC}.
FT   STRAND      140    149       {ECO:0000244|PDB:2DSC}.
FT   HELIX       153    155       {ECO:0000244|PDB:2DSC}.
FT   STRAND      164    166       {ECO:0000244|PDB:3AC9}.
FT   STRAND      169    174       {ECO:0000244|PDB:2DSC}.
FT   HELIX       175    177       {ECO:0000244|PDB:2DSC}.
FT   HELIX       178    189       {ECO:0000244|PDB:2DSC}.
FT   STRAND      192    194       {ECO:0000244|PDB:2DSC}.
FT   HELIX       195    207       {ECO:0000244|PDB:2DSC}.
FT   TURN        211    213       {ECO:0000244|PDB:2DSB}.
FT   HELIX       214    216       {ECO:0000244|PDB:2DSB}.
SQ   SEQUENCE   219 AA;  24328 MW;  6574E0BF1EA2BB26 CRC64;
     MESQEPTESS QNGKQYIISE ELISEGKWVK LEKTTYMDPT GKTRTWESVK RTTRKEQTAD
     GVAVIPVLQR TLHYECIVLV KQFRPPMGGY CIEFPAGLID DGETPEAAAL RELEEETGYK
     GDIAECSPAV CMDPGLSNCT IHIVTVTING DDAENARPKP KPGDGEFVEV ISLPKNDLLQ
     RLDALVAEEH LTVDARVYSY ALALKHANAK PFEVPFLKF
//
